1-[5-(3-Chloro-5-fluoroanilino)-2,1,3-benzoxadiazol-4-yl]pyrrole-2,5-dione | 1422955-43-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶二唑类
• 英文名称: 1-[5-(3-Chloro-5-fluoroanilino)-2,1,3-benzoxadiazol-4-yl]pyrrole-2,5-dione
• 英文别名: 1-[5-(3-chloro-5-fluoroanilino)-2,1,3-benzoxadiazol-4-yl]pyrrole-2,5-dione
• CAS: 1422955-43-8
• 化学式: C₁₆H₈ClFN₄O₃
• 分子量: 358.716
• InChiKey: SNGUUOVVLJIQEU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  25
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  88.3
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  5-氯-4-硝基-2,1,3-苯噁二唑 在 tin(II) chloride dihdyrate 、 溶剂黄146 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 7.0h， 生成 1-[5-(3-Chloro-5-fluoroanilino)-2,1,3-benzoxadiazol-4-yl]pyrrole-2,5-dione
  参考文献：
  名称：

  Development of Inhibitors of the PAS-B Domain of the HIF-2α Transcription Factor

  摘要：

  Hypoxia inducible factors (HIFs) are heterodimeric transcription factors induced in a variety of pathophysiological settings, including cancer. We describe the first detailed structure-activity relationship study of small molecules designed to inhibit HIF-2 alpha-ARNT heterodimerization by binding an internal cavity of the HIF-2 alpha PAS-B domain. Through a series of biophysical characterizations of inhibitor-protein interactions (NMR and X-ray crystallography), we have established the structural requirements for artificial inhibitors of the HIF-2 alpha-ARNT PAS-B interaction. These results may serve as a foundation for discovering therapeutic agents that function by a novel mode of action.

  DOI：

  10.1021/jm301847z

文献信息

• Development of Inhibitors of the PAS-B Domain of the HIF-2α Transcription Factor
  作者：Jamie L. Rogers、Liela Bayeh、Thomas H. Scheuermann、Jamie Longgood、Jason Key、Jacinth Naidoo、Lisa Melito、Cameron Shokri、Doug E. Frantz、Richard K. Bruick、Kevin H. Gardner、John B. MacMillan、Uttam K. Tambar

  DOI：10.1021/jm301847z

  日期：2013.2.28

  Hypoxia inducible factors (HIFs) are heterodimeric transcription factors induced in a variety of pathophysiological settings, including cancer. We describe the first detailed structure-activity relationship study of small molecules designed to inhibit HIF-2 alpha-ARNT heterodimerization by binding an internal cavity of the HIF-2 alpha PAS-B domain. Through a series of biophysical characterizations of inhibitor-protein interactions (NMR and X-ray crystallography), we have established the structural requirements for artificial inhibitors of the HIF-2 alpha-ARNT PAS-B interaction. These results may serve as a foundation for discovering therapeutic agents that function by a novel mode of action.